Introduction

Dual mobility (DM) total hip arthroplasty (THA) prostheses are designed to increase stability. In the setting of primary and revision THA, DM THA are used most frequently for dysplasia and instability diagnoses, respectively. As the use of DM THA continues to increase, with 8,031 cases logged in the American Joint Replacement Registry from 2012–2018, characterizing in vivo damage and clinical failure modes are important to report.

Introduction: Total hip arthroplasty is one of the most frequently performed surgical procedures, with implants usually giving over 90% survival at 10 years. The failure rate is primarily due to aseptic loosening often associated with progressive bone stock loss. Impaction of cancellous morselized allografts with cement can be used for revision total hip arthroplasty in such cases. There is increasing interest in the use of synthetic bone graft substitutes as extenders to allograft due to the shortage and variable quality of allograft. A chemically-pure synthetic calcium phosphate (CaP) allograft extender is compared with allograft alone for acetabular and/or femoral revisions using the Impaction Grafting technique. Methods: 96 hips in 94 patients underwent revision hip arthroplasty using impaction grafting at 4 sites. Hip revision using impaction grafting was carried out using the Exeter X-Change Instrumentation system, using an Exeter Stem and/or a cemented polyethylene cup. Patients were randomized to receive allograft or CaP plus allograft in a 50:50 volume. Clinical and radiographic assessment was conducted pre-operatively and immediately post-operatively and at 6, 12 and 24 months. Clinical assessments included Harris Hip, Oxford and Charnley modified Merle d’Aubigne scores. Clinical complications were also recorded. Radiographs were assessed for the graft quality, radiolucent lines, lyses or migration, and incorporation of graft. The X-rays were also independently reviewed by an experienced author. Results: The mean age was 70.2 years (range 41–89 years) with 58 males and 36 females. A total of 40 femoral revisions and 88 acetabular revisions were conducted. There were 46 patients in the ApaPore group, 49 patients in the allograft group and 1 patient who received CaP/allograft and allograft for an acetabular and femoral revision respectively. No deep infections or adverse events due to the CaP were reported, with no significant difference in complication rates including revision and re-operations. No significant difference in acetabular migration, femoral subsidence, radiolucencies and lyses between the groups was observed. The independent review found no difference between the groups in terms of migration. The bone density was apparently greater for the ApaPore group at 12 months (p=0.001) and 24 months (p=0.012) although the significance of this is unclear. No significant difference in the clinical measures was observed between the groups. Conclusion: CaP is comparable with allograft in terms of performance and safety when used as an allograft extender for total hip revision arthroplasty using impaction grafting

Modular femoral stem provides significant flexibility in total hip revision arthroplasty. There have been few clinical studies that have dealt with modular stem. We have evaluated the clinical and radiographic performance of 59 patients with distal fix modular Link MP stem. The average follow-up period was 6.4 years. The average Harris hip score was improved from 47 to 87.6. Of 19 patients with trochanteric osteotomy, greater trochanter was displaced in four patients. Re-revision was done to five patients. Three were for subsidence, one of them showed dissociation of the coupling part and the other two were for a nonunion of osteotomy site. There was no statistical relation (p=0.40) between stem subsidence and bone deficiency; the subsidence may have been too small for the canal. As a result of last follow-up, survival rate was 91.5 %(CI 95%, 89–101), but there was no case of recurrent dislocation or femoral stem fracture

Xenografts of bovine bone were used successfully for years with a minimum acceptable rate of side effects in total hip revision arthroplasty for filling large bone defects. The great majority of them was withdrawn from the market when any biological product of bovine origin was considered as a potential carrier of prions infection. However, current EEC regulations permit their surgical therapeutic use if obtained from cattle under 6 months of age, which are supposed to be not at risk of prion transmission. Lubboc, a purified trabecular bone matrix containing only type-1 collagen and hydroxyapatite, fulfils this requirement. From 2001 to 2003 we used this product in fragments (chips) to fill bone defects of the acetabulum before screwing the acetabular rings in 37 patients. No massive grafts were implanted. Minimum follow-up was 12 months, maximum 27 months. Four subjects were lost to follow-up. The fate of the grafts was evaluated for evidence of union, remodelling, resorption, migration of the rings or fracture of the newly formed bone. No significant adverse events were registered. If the risk of transmitting infectious agents is excluded or minimised according to the present legislation, it seems unjustified to remove xenografts from the options available to orthopaedic surgeons, considering the problems of bone stock deficiency and reconstruction in hip arthroplasty revision surgery